Figure 3.

MALT1 plays a T cell-intrinsic role in Treg development. (A) Percentage of Tregs (Foxp3⁺CD25⁺CD4⁺ T cells) in the thymus, spleen and lymph nodes of Malt1-WT and Malt1-KO mice without skin lesions (WT: n = 4 and KO: n = 4, age 10–12 weeks). (B) Percentage of Tregs (Foxp3⁺CD25⁺ CD4⁺ T cells) in the thymus, spleen and lymph nodes of older WT and Malt1-KO mice with skin lesions (WT: n = 4 and KO: n = 6, age 6.5–8.5 months). (C) Percentage of Tregs (Foxp3⁺CD25⁺CD4⁺ T cells) in the thymus, spleen and lymph nodes of WT (Malt1^FL/FLCD4-Cre^+/+, n = 4), and T-KO (Malt1^FL/FLCD4-Cre^Tg/+, n = 4) mice. (D) Percentage of splenic Tregs (Foxp3⁺CD4⁺ T cells) expressing CTLA-4 on their surface after stimulation for 4 h with PMA and IO in WT (n = 5) and Malt1-KO (n = 5) mice. The mean ± SEM is indicated on the graphs. The statistical significance between groups was calculated with an unpaired 2-tailed Student's t-test: **P < 0.01 and ****P < 0.0001.